These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2701646)

  • 1. Options for the treatment of serious infections with interleukin-1.
    van der Meer JW
    Biotherapy; 1989; 1(4):313-7. PubMed ID: 2701646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection of neutropenic mice from lethal Candida albicans infection by recombinant interleukin 1.
    Van't Wout JW; Van der Meer JW; Barza M; Dinarello CA
    Eur J Immunol; 1988 Jul; 18(7):1143-6. PubMed ID: 3261247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of recombinant interleukin-1 and recombinant tumor necrosis factor on non-specific resistance to infection.
    van der Meer JW
    Biotherapy; 1988; 1(1):19-25. PubMed ID: 3079457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection.
    van der Meer JW; Barza M; Wolff SM; Dinarello CA
    Proc Natl Acad Sci U S A; 1988 Mar; 85(5):1620-3. PubMed ID: 3125553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibacterial resistance induced by recombinant interleukin 1 in myelosuppressed mice: effect of treatment schedule and correlation with colony-stimulating activity in the bloodstream.
    Campanile F; Binaglia L; Boraschi D; Tagliabue A; Fioretti MC; Puccetti P
    Cell Immunol; 1990 Jun; 128(1):250-60. PubMed ID: 2111738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential gene expression for IL-1 receptor antagonist, IL-1, and TNF receptors and IL-1 and TNF synthesis may explain IL-1-induced resistance to infection.
    Vogels MT; Mensink EJ; Ye K; Boerman OC; Verschueren CM; Dinarello CA; van der Meer JW
    J Immunol; 1994 Dec; 153(12):5772-80. PubMed ID: 7989774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of recombinant interleukin 6 and recombinant interleukin 1 on nonspecific resistance to infection.
    Van der Meer JW; Helle M; Aarden L
    Eur J Immunol; 1989 Feb; 19(2):413-6. PubMed ID: 2495225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Enhancement of host defence against infection with Listeria monocytogenes in newborn mice by various recombinant cytokines].
    Chen Y
    Hokkaido Igaku Zasshi; 1991 Jan; 66(1):41-8. PubMed ID: 1900802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of fatal infections by recombinant human interleukin 1 alpha in normal and anticancer drug-treated mice.
    Morikage T; Mizushima Y; Sakamoto K; Yano S
    Cancer Res; 1990 Apr; 50(7):2099-104. PubMed ID: 2317799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-1 as a possible agent for treatment of infection.
    van der Meer JW; Vogels M; Curfs JH; Eling WM
    Eur J Clin Microbiol Infect Dis; 1993; 12 Suppl 1():S73-7. PubMed ID: 8477769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-1-induced nonspecific resistance to bacterial infection in mice is not mediated by glucocorticosteroids.
    Vogels MT; Sweep CG; Hermus AR; van der Meer JW
    Antimicrob Agents Chemother; 1992 Dec; 36(12):2785-9. PubMed ID: 1482145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of acute-phase proteins in interleukin-1-induced nonspecific resistance to bacterial infections in mice.
    Vogels MT; Cantoni L; Carelli M; Sironi M; Ghezzi P; van der Meer JW
    Antimicrob Agents Chemother; 1993 Dec; 37(12):2527-33. PubMed ID: 7509141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of interleukin-8 on nonspecific resistance to infection in neutropenic and normal mice.
    Vogels MT; Lindley IJ; Curfs JH; Eling WM; van der Meer JW
    Antimicrob Agents Chemother; 1993 Feb; 37(2):276-80. PubMed ID: 8452358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous cytokines during a lethal infection with Listeria monocytogenes in mice.
    Nakane A; Yamada K; Hasegawa S; Mizuki D; Mizuki M; Sasaki S; Miura T
    FEMS Microbiol Lett; 1999 Jun; 175(1):133-42. PubMed ID: 10361718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of interleukin-6, tumour necrosis factor and interleukin-1 during Listeria infection.
    Liu Z; Simpson RJ; Cheers C
    Immunology; 1995 Aug; 85(4):562-7. PubMed ID: 7558150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic potential of interleukin-1 and tumor necrosis factor on hematopoietic stem cells.
    Moreb J; Zucali JR
    Leuk Lymphoma; 1992 Nov; 8(4-5):267-75. PubMed ID: 1290956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The in vivo and in vitro effects of interleukin-1 and tumor necrosis factor on murine cytomegalovirus infection.
    van der Meer JW; Rubin RH; Pasternack M; Medearis DN; Lynch P; Dinarello CA
    Biotherapy; 1989; 1(3):227-31. PubMed ID: 2561979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic inhibitors of tumor necrosis factor production exert differential effects in lethal endotoxemia and in infection with live microorganisms in mice.
    Netea MG; Blok WL; Kullberg BJ; Bemelmans M; Vogels MT; Buurman WA; van der Meer JW
    J Infect Dis; 1995 Feb; 171(2):393-9. PubMed ID: 7844376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradoxical synergistic effects of tumour necrosis factor and interleukin 1 in murine gut-derived sepsis with Pseudomonas aeruginosa.
    Matsumoto T; Tateda K; Miyazaki S; Furuya N; Ohno A; Ishii Y; Hirakata Y; Yamaguchi K
    Cytokine; 1999 May; 11(5):366-72. PubMed ID: 10328876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-1 and related pro-inflammatory cytokines in the treatment of bacterial infections in neutropenic and non-neutropenic animals.
    van der Meer JW; Vogels MT; Kullberg BJ
    Biotherapy; 1994; 7(3-4):161-7. PubMed ID: 7865347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.